Inclusion Criteria:

          -  Histologically confirmed diagnosis of multiple myeloma.

          -  Received prior autologous stem cell transplantation as first line therapy for multiple
             myeloma with subsequent disease relapse/progression.

          -  Failed 1 or 2 lines of treatment for multiple myeloma. A line of treatment includes
             all therapy including induction, transplant, and maintenance administered in a
             sequence in the absence of relapse/progression. Once relapse/progression occurs and
             subsequently the anti-myeloma treatment is changed, a new line of treatment has begun.
             Local radiation or corticosteroids will not be considered treatment for multiple
             myeloma.

          -  Received 2 to 6 cycles of induction therapy per standard of care prior to 2nd
             autologous stem cell transplantation

          -  Received standard of care melphalan conditioning for 2nd autologous stem cell
             transplantation, is currently Day +80 to +120 following transplant, and is responding
             to therapy (partial response or better as compared to pre-induction assessment.

          -  All US study participants must be registered into the mandatory POMALYST REMS® program
             and be willing and able to comply with the requirements of the POMALYST REMS® program.
             For Canadian sites, patients will followed according to the Pomalidomide pregnancy
             prevention program

          -  Females of reproductive potential within the US must agree to adhere to the scheduled
             pregnancy testing as required in the POMALYST REMS® program. For Canadian sites,
             patients will followed according to the Pomalidomide pregnancy prevention program

          -  At least 18 and no more than 75 years of age at enrollment.

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Normal bone marrow and organ function as defined as ALL of the following:

               -  Absolute neutrophil count ≥ 1000/mm^3

               -  Platelets ≥ 75,000/mm^3 (transfusions not permitted within 7 days of screening)

               -  Total bilirubin ≤ 2.0 x institutional upper limit of normal (IULN)

               -  AST(SGOT)/ALT(SGPT) ≤ 3.0 x IULN

               -  Creatinine clearance ≥ 15 mL/min

          -  Females of childbearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control, abstinence) prior to study entry through
             Day +100 visit. Should a woman become pregnant or suspect she is pregnant while
             participating in this study, she must inform her treating physician immediately.

          -  Able to understand and willing to sign an Institutional Review Board (IRB) approved
             written informed consent document.

        Exclusion Criteria:

          -  Refractory to elotuzumab and/or pomalidomide, defined as progressive disease or
             clinical relapse on therapy or within 60 days following completion of therapy. Prior
             exposure to elotuzumab and/or pomalidomide is allowed as long as patient is not
             refractory to these agents.

          -  More than one prior transplant prior to study entry with the exception of tandem
             transplantation. Tandem transplantation is defined as two autologous stem cell
             transplants that occur within 9 months of one another, and the patient did not have
             disease progression in the period between the two transplants.

          -  Presence of peripheral neuropathy ≥ grade 3 based on National Cancer Institute (NCI)
             Common Terminology Criteria for Adverse Events (CTCAE) v 4.0

          -  History of plasma cell leukemia or MM central nervous system (CNS) involvement.

          -  Receiving renal replacement therapy, hemodialysis, or peritoneal dialysis.

          -  Diagnosed with another concurrent malignancy requiring treatment.

          -  Known HIV or active hepatitis A, B, or C. Antidoby testing not required for screening

          -  Known hypersensitivity to pomalidomide, dexamethasone, or any excipients in
             elotuzumab, formulation, or recombinant protein

          -  Receiving any other investigational agents within 14 days prior to enrollment.

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac
             arrhythmia.

          -  Pregnant and/or breastfeeding. Females of childbearing potential must have two
             negative pregnancy tests. The first test should be performed within 10-14 days of
             study entry, and the second test within 24 hours prior to prescribing pomalidomide.